U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H22FN3O3
Molecular Weight 359.3947
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ENROFLOXACIN

SMILES

CCN1CCN(CC1)C2=CC3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O

InChI

InChIKey=SPFYMRJSYKOXGV-UHFFFAOYSA-N
InChI=1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)

HIDE SMILES / InChI

Molecular Formula C19H22FN3O3
Molecular Weight 359.3947
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including, http://file.scirp.org/pdf/OJVM_2016022615035704.pdf, https://actualidadveterinaria.files.wordpress.com/2011/10/fluoroquinolones-then-and-now.pdf

Enrofloxacin was developed by Bayer for the treatment of broad spectrum of bacterial infections in animals (cats and dogs). The drug exerts its action by inhibiting DNA Topoisomerase II (Gyrase) and DNA Topoisomerase IV (Topo IV), two major bacterial topoisomerase. Enrofloxacin was shown to be metabolized to ciprofloxacin and may cross the blood brain barrier in the animals.

CNS Activity

Curator's Comment: Enrofloxacin crosses the blood-brain barrier in dogs and may cause CNS stimulation

Originator

Curator's Comment: Enrofloxacin was synthesized by Bayer researchers Grohe and Peterson in 1980 # Bayer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
BAYTRIL

Approved Use

Baytril Antibacterial Tablets and Injectable Solution are indicated for the management of diseases in dogs and cats associated with bacteria susceptible to enrofloxacin.

Launch Date

2006
PubMed

PubMed

TitleDatePubMed
Susceptibility of Arcobacter butzleri isolates to 23 antimicrobial agents.
2001 Dec
Information on adverse drug reaction in cats.
2001 Dec 15
Antibiotic resistance from down on the chicken farm.
2001 Jan-Feb
Pathogenicity and drug susceptibility of the Pasteurella anatis isolated in chickens in Taiwan.
2001 Jul-Sep
The effect of organic acids on the control of post-weaning oedema disease of piglets.
2001 Jun
In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
2001 Jun
In vitro antibiotic sensitivity of strains of Ornithobacterium rhinotracheale isolated in The Netherlands between 1996 and 1999.
2001 Nov 17
Prevalence and mechanism of resistance against macrolides and lincosamides in Streptococcus suis isolates.
2001 Nov 26
Bioequivalence of four preparations of enrofloxacin in poultry.
2001 Oct
Absorption spectra of the 4f electron transitions of the praseodymium complex with 1-cyclopropyl-6-fluoro-1,4-dihydro-7-(4-ethyl-1-piperazinyl) -4-oxo-3-quinoline carboxylic acid hydrochloride and its analytical application.
2001 Sep
Antimicrobial susceptibility of Pasteurella multocida isolated from cattle and pigs.
2001 Sep
Antimicrobial susceptibility of udder pathogens isolated from dairy herds in the west littoral region of Uruguay.
2002
Effect of enrofloxacin treatment on plasma endotoxin during bovine Escherichia coli mastitis.
2002 Apr
Bacterial resistance to quinolone antibiotics in Poland.
2002 Apr
Biofilm bacteria: formation and comparative susceptibility to antibiotics.
2002 Apr
Salmonella enterica serotype Typhimurium DT 104 antibiotic resistance genomic island I in serotype paratyphi B.
2002 Apr
Serovars of Salmonella isolated from Danish turkeys between 1995 and 2000 and their antimicrobial resistance.
2002 Apr 13
Questions study on Escherichia coli susceptibility.
2002 Apr 15
Idiosyncratic reaction to enrofloxacin in cats.
2002 Apr 27
Idiosyncratic reaction to enrofloxacin in cats.
2002 Apr 27
Multiresidue determination of (fluoro)quinolone antibiotics in swine kidney using liquid chromatography-tandem mass spectrometry.
2002 Apr 5
The use of liposomal enrofloxacin for intracellular infections in Kangal dogs and visualization of phagocytosis of liposomes.
2002 Aug
In vitro development of resistance to enrofloxacin, erythromycin, tylosin, tiamulin and oxytetracycline in Mycoplasma gallisepticum, Mycoplasma iowae and Mycoplasma synoviae.
2002 Aug 2
Anticryptosporidial prophylactic efficacy of enrofloxacin and paromomycin in chickens.
2002 Feb
Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration.
2002 Feb
Using nonaqueous capillary electrophoresis to analyze several quinolones in pig kidney samples.
2002 Feb
Elimination of mycoplasma from leukemia-lymphoma cell lines using antibiotics.
2002 Feb
Comparative in vitro activity of 16 antimicrobial agents against Actinobacillus pleuropneumoniae.
2002 Jan
Monoclonal-based enzyme-linked immunosorbent assay and immunochromatographic assay for enrofloxacin in biological matrices.
2002 Jan
Susceptibility of human isolates of Salmonella typhimurium DT 104 to antimicrobial agents used in human and veterinary medicine.
2002 Jan
Blindness now attributed to enrofloxacin therapy in a previously reported case of a cat with acromegaly treated by cryohypophysectomy.
2002 Jan
Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid.
2002 Jan
Spectrophotometric determination of ciprofloxacin, enrofloxacin and pefloxacin through charge transfer complex formation.
2002 Jan 1
Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections.
2002 Jan 15
Antibiotic resistance. Livestock feed ban preserves drugs' power.
2002 Jan 4
Pathotypes of avian Escherichia coli as related to tsh-, pap-, pil-, and iuc-DNA sequences, and antibiotic sensitivity of isolates from internal tissues and the cloacae of broilers.
2002 Jan-Mar
Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep.
2002 Jul
Use of enrofloxacin for treatment of large-form Haemobartonella felis in experimentally infected cats.
2002 Jul 15
Antimicrobial multiresistance in bacteria isolated from freshwater Chilean salmon farms.
2002 Jul 3
LC determination of enrofloxacin.
2002 Jun 15
Identification and antimicrobial susceptibility of Staphylococcus chromogenes isolates from intramammary infections of dairy cows.
2002 Jun 20
Molecular epidemiology of feline bordetellosis in two animal shelters in California, USA.
2002 Jun 25
Concentration of enrofloxacin and its metabolite ciprofloxacin in canine matrices of the locomotor system.
2002 Mar
Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Escherichia coli, and Salmonella choleraesuis recovered from Taiwanese swine.
2002 Mar
Ciprofloxacin resistance in Campylobacter jejuni evolves rapidly in chickens treated with fluoroquinolones.
2002 Mar 15
Administration of enrofloxacin and capsaicin to chickens to achieve higher maximal serum concentrations.
2002 Mar 16
In vitro antimicrobial susceptibility of 183 Pseudomonas aeruginosa strains isolated from dogs to selected antipseudomonal agents.
2002 May
Bacterial colonization of intravenous catheters in young dogs suspected to have parvoviral enteritis.
2002 May 1
Bayer seeks veterinary, industry backing before Baytril hearing.
2002 May 15
Determination of ciprofloxacin, enrofloxacin and flumequine in pig plasma samples by capillary isotachophoresis--capillary zone electrophoresis.
2002 May 25
Patents

Patents

Sample Use Guides

The dose range of Baytril (Enrofloxacin) Antibacterial Tablets in dogs and cats is 5 to 20 mg/kg (2.27 to 9.07 mg/lb) of body weight, either as a single dose or divided into two (2) equal daily doses administered at twelve (12) hour intervals. The dose of Baytril Injectable Solution for dogs is 2.5 mg/kg (1.13 mg/lb) as a single injection. The injectable dose should be followed by oral tablet treatment in 12 hours.
Route of Administration: Other
In Vitro Use Guide
The minimum inhibitory concentration (MIC) enrofloxacin against 24 Sicilian isolates of Mycoplasma agalactiae, the causative organism of contagious agalactia were determined in vitro by a broth dilution method. Enrofloxacin was effective antimicrobial in vitro with a range of MIC values from 0.125 to 0.500 microg/ml and an MIC(50) of 0.203 and MIC(90) of 0.365 microg/ml.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:43:50 GMT 2023
Edited
by admin
on Fri Dec 15 15:43:50 GMT 2023
Record UNII
3DX3XEK1BN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ENROFLOXACIN
GREEN BOOK   HSDB   INN   MART.   MI   USAN   USP   USP-RS  
INN   USAN  
Official Name English
ENROFLOXACIN [USP MONOGRAPH]
Common Name English
ENROFLOXACIN [HSDB]
Common Name English
ENROFLOXACIN [MI]
Common Name English
ENROFLOXACIN FOR VETERINARY USE [EP MONOGRAPH]
Common Name English
ENROFLOXACIN FOR VETERINARY USE [EP IMPURITY]
Common Name English
ENROFLOXACIN [USP IMPURITY]
Common Name English
BAYTRIL
Brand Name English
ENROFLOXACIN [GREEN BOOK]
Common Name English
ENROFLOXACIN [USP-RS]
Common Name English
ENROFLOXACIN [USAN]
Common Name English
ENROFLOXACIN [MART.]
Common Name English
ENROFLOXACIN FOR VETERINARY USE
EP  
Common Name English
BAY VP 2674
Code English
enrofloxacin [INN]
Common Name English
1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Systematic Name English
NSC-758616
Code English
Classification Tree Code System Code
WHO-VATC QJ01MA90
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
CFR 21 CFR 556.226
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
CFR 21 CFR 520.812
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
CFR 21 CFR 524.802
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
NCI_THESAURUS C795
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
CFR 21 CFR 522.812
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
Code System Code Type Description
WIKIPEDIA
Enrofloxacin
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
PUBCHEM
71188
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
FDA UNII
3DX3XEK1BN
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
RXCUI
24192
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY RxNorm
SMS_ID
300000023676
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
NCI_THESAURUS
C72660
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
NSC
758616
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
INN
5963
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
USAN
Z-54
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
HSDB
6952
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
EPA CompTox
DTXSID1045619
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
CAS
93106-60-6
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
ChEMBL
CHEMBL15511
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
DRUG BANK
DB11404
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
MESH
C052904
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
MERCK INDEX
m4916
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY Merck Index
DAILYMED
3DX3XEK1BN
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
RS_ITEM_NUM
1235900
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
CHEBI
35720
Created by admin on Fri Dec 15 15:43:50 GMT 2023 , Edited by admin on Fri Dec 15 15:43:50 GMT 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY